Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Strategy house McKinsey & Co has released a report on M&A in Pharma - interesting to read the suggested war chests that have been accumulated!
https://www.mckinsey.com/business-functions/m-and-a/our-insights/a-new-prescription-for-m-and-a-in-pharma?cid=soc-app
Great to have caught up with all the research and thinking over the last 18 hours or so - some really good quality material so thank you all....and good to see that all the name calling from yesterday morning evaporated through the day!
Some news on the UK’s R rate
https://apple.news/Ap6Dn4CamRG-w5ny6mtchHw
May have been posted yesterday - if not:
https://apple.news/Ays-OTYHqTyyG9C3so-t_mQ
Graking - it suits my purpose because I know that in the COVID read out for SNG treatment the mean age was 57.8 and median age was 58.5 and for COPD mean was 67 - data available from company presentations on their website
Pretty obvious that this is a tactical RNS as is the COPD interim results - required to bolster evidence of safety, which it has done. RM can now point regulators to 3 trial data sets....this now paves the way for EUA for Covid 19 which is what shareholders are waiting for. RM also suggested that there will be ‘news on news’ so don’t think we will be waiting too much longer!
Think somewhere along the line, in one of RMs interviews, he alluded to the fact that their P2 trial was set up based upon P3 principles after taking regulatory guidance - hence regarded as gold standard - randomised, double blinded, placebo - on the way to achieve quickest possible EUA
Yes you’re right and whilst he’s talking about direct inhalation of antibody treatment to the lungs for the TILS patent - of course his wider statement is a clear endorsement of SNG method for delivery of interferon. The main point being all the viral damage initially takes place in the respiratory system - let’s get back to the science.
A further point from this video is he talks about the clear planning that leads to the 3 years for the patent process - and cites being confirmation of the clear direction that TILS has. Very much the same can be said for SNG
Yes - looked her up on LinkedIn....been writing as a freelancer there for 6 months - oh and she has a level 1 Chartered Financial Analyst qualification....before that she worked for the British Army - great credentials for current role!
Just to put another perspective on it - if Trump does tonight highlight some new therapy from a US pharma - surely that would also put pressure on that pharma’s competitors to bring something forward as a response. Whichever way it pans out tonight can only see it reinforcing SNG’s position and credentials
Sparkle - I too have previously sold a business to a US public co and actually found the exact opposite - little point in granting exclusivity if you have a number of suitors and it would be a strategic acquisition for any of them. Armed with multiple term sheets is the best way to exact the optimum deal for shareholders - in any case full due diligence will follow any formal offer.
Potentially RM is sitting on a therapy that many will want and many will be wanting to present their case. Meanwhile his main attention should be to continue to derisk the opportunity for prospective buyers - ie get regulatory approval, have the COPD trial evaluated, have the supply chain set up and confirmed for maximum doses - each successful stage raises the value for any deal
CW25 - Good to see you again! Am very much in the same boat as you - slightly lower figure - but very happy to hold. Must admit I am much less active here than pre results because all the emotions being demonstrated are very similar to previously and there’s not much reassurance to give to newcomers other than trust the SNG team and try to be patient easier said than done!
Nolupus bought into SNG well before £1 - he then waited before topping up until the results were out - his strategy was to average up. He gets a bit of a bad press from Eva yet I found his posts of interest, well positioned and often thought provoking. Has been a very valuable member of this BB imho
Nolupus - completely agree - from a financial investment perspective its the COPD therapy, with a recurring and embedded value attached to it, that justifies a high multiple in any deal....Covid is a (big) bonus for any acquirer though will add to the multiple of course.